Konyang University Hospital in South Korea relies on Molecular Health's MH Guide for personalized cancer medicine

HEIDELBERG, GERMANY / DAEJEONG, SOUTH KOREA - Media OutReach^[1] - 16 July 2021 - Konyang University Hospital^[2] in Daejeong, South Korea, will rely on MH Guide in the personalized treatment of its cancer patients. This is the result of an agreement between the hospital and Molecular Health^[3]. It makes Konyang University Hospital the first facility in South Korea to use MH Guide. "Precision medicine in cancer care enables personalized treatment through comprehensive analysis of genes, clinical information and drugs. With our NGS system and MH Guide, we have a complete precision medicine ecosystem that will enable us to provide world-class cancer care," said Yoon Dae-seong, Director of the Cancer Center at Konyang University Hospital.

MH Guide is an analysis software that helps molecular pathologists and oncologists interpret NGS data and make treatment decisions. The software automatically detects relevant gene variants from molecular information and identifies treatment options based on the molecular profile and ongoing trials that may be relevant to the patient. To do this, MH Guide matches molecular patient data with data derived from one of the largest growing and Molecular Health-owned knowledge platforms (Dataome). This makes MH Guide an evidence-based decision support tool that enables physicians and molecular pathologists to keep pace with the rapidly growing stock of medical knowledge and make it actionable in treating their patients.

"We are very pleased to collaborate with Konyang University Hospital. We are convinced that with MH Guide we can make an important contribution to the personalized care for Korean patients," said Stephan Hettich, SVP, Head of Sales & Business Development, APAC, at Molecular Health.

References

1. ^{^} Media OutReach (www.media-outreach.com)
2. ^{^} Konyang University Hospital (www.kyuh.ac.kr)
3. ^{^} Molecular Health (www.molecularhealth.com)